8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): April 24, 2003

                                PerkinElmer, Inc.
- --------------------------------------------------------------------------------
               (Exact name of registrant as specified in charter)

      Massachusetts                   1-5075                     04-2052042
- --------------------------------------------------------------------------------
 (State or other juris-             (Commission                 (IRS Employer
diction of incorporation)           File Number)             Identification No.)


45 William Street, Wellesley, Massachusetts                             02481
- --------------------------------------------------------------------------------
  (Address of principal executive offices)                            (Zip Code)

       Registrant's telephone number, including area code: (781) 237-5100

                                 Not applicable
- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)

ITEM 9. REGULATION FD DISCLOSURE (INFORMATION FURNISHED PURSUANT TO ITEM 12,
"DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION").

      On April 24, 2003, PerkinElmer, Inc. announced its financial results for
the quarter ended March 30, 2003. The full text of the press release issued in
connection with the announcement is attached as Exhibit 99.1 to this Current
Report on Form 8-K.

      In accordance with the procedural guidance in SEC Release No. 33-8216, the
information in this Form 8-K and the Exhibit attached hereto is being furnished
under "Item 9. Regulation FD Disclosure" rather than under "Item 12. Disclosure
of Results of Operations and Financial Condition." The information shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934
(the "Exchange Act") or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

                                    SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: April 24, 2003                      PerkinElmer, Inc.

                                          By:   /s/ Robert F. Friel
                                                -------------------
                                                Robert F. Friel,
                                                Senior Vice President
                                                and Chief Financial Officer

                                  EXHIBIT INDEX



Exhibit No.                          Description
- -----------                          -----------
                                  
99.1                                 Press release dated April 24, 2003

EX-99.1

                                                                    Exhibit 99.1

FOR IMMEDIATE RELEASE
24 April 2003

                    PERKINELMER ANNOUNCES EARNINGS PER SHARE
                         IN LINE WITH PREVIOUS ESTIMATES

                  -     REVENUE GROWTH OF 4%

                  -     GAAP EPS FROM CONTINUING OPERATIONS OF $.03 PER SHARE,
                        UP FROM A LOSS OF ($.17) PER SHARE IN Q1 02

                  -     $24M OPERATING CASH FLOW; $55M IMPROVEMENT FROM Q1 02

                  -     LIFE AND ANALYTICAL SCIENCES INTEGRATION ON TRACK

BOSTON - PerkinElmer, Inc. (NYSE: PKI) today announced first quarter 2003 GAAP
earnings per share from continuing operations of $.03 on revenue of $358.4
million, compared to a GAAP loss per share from continuing operations of ($.17)
and revenue of $346.3 million in the first quarter of 2002. The first quarter
2003 results reflect intangibles amortization of $7.2 million, or approximately
$.04 per share. These earnings are consistent with the company's January 2003
estimate for the quarter of $.02 to $.05 per share on a GAAP basis.

"We were pleased to deliver earnings per share and cash flow that are
significantly improved from last year and within the range of our previous
guidance," said Gregory L. Summe, chairman and CEO of the Company. "The
integration of our Life and Analytical Sciences unit is progressing well and our
plans are on track to meet or exceed our targeted cost reductions," added Summe.

Revenue from continuing operations in the first quarter of 2003 was $358.4
million, up 4% from the same period of 2002. The comparative increase was driven
by 20% growth in Optoelectronics and 11% growth in Analytical Instruments,
offset by revenue declines in Life Sciences and Fluid Sciences.


                                     -more-



The Company generated operating cash flow of $24.1 million in the first quarter
of 2003, compared to a use of cash of ($31.1) million in the same period of
2002. During the 2003 quarter, the Company reduced working capital by $24.0
million, which includes an $11.0 million increase in an accounts receivable
securitization program. During the first quarter of 2003, the Company paid down
$15.0 million of debt, and cash and equivalents were $129.8 million at the end
of the quarter.

Including the impact of discontinued operations, net earnings on a GAAP basis
for the first quarter of 2003 were $.02 per share compared to a loss per share
of ($1.18) for the same period of 2002. The net loss for the first quarter of
2002 included a ($.07) per share loss from discontinued operations and a ($.94)
loss per share resulting from the effect of an accounting change.

For the first quarter of 2002, the Company's GAAP results from continuing
operations were a loss of ($.17) per share on revenue of $346.3 million. The
first quarter of 2002 results included $26.0 million of net charges comprised of
restructuring charges, gain on sale, an inventory write-down and acquisition
related charges, as well as intangibles amortization of $7.1 million. The
aggregate effect of these items for the first quarter of 2002 was approximately
$.19 per share.

Financial overview by reporting segment:

LIFE SCIENCES reported revenue of $103.9 million for the first quarter of 2003,
down 11% compared to revenue of $116.8 million for the first quarter of 2002.
Strong revenue growth in genetic screening during the quarter and overall
segment growth in reagents, consumables and service were offset by lower
instruments sales compared to the 2002 quarter. Instruments sales during the
2003 quarter continued to be impacted by pressure on capital spending within
most end markets, particularly large pharmaceutical company markets. The
segment's GAAP operating loss for the first quarter of 2003 was $.4 million
versus a $1.0 million operating loss in the same period of 2002. The results for
the first quarter of 2003 include intangibles amortization of $5.3 million. The
operating loss for the first quarter of 2002 included $8.7 million of
restructuring and acquisition-related charges, as well as intangibles
amortization of $5.5 million.

ANALYTICAL INSTRUMENTS reported revenue of $128.3 million for the first quarter
of 2003, representing an 11% increase compared to revenue of $115.5 million for
the comparable quarter of 2002. The Company experienced good growth in each
of its major end markets, with particular strength in environmental
applications and pharmaceutical QA/QC. The segment's GAAP operating profit for
the first quarter of 2003 was $12.0 million, compared to operating profit of
$8.8 million for the same period of 2002. The results for the first quarter of
2003 include intangibles amortization of $1.1 million. The first quarter of 2002
results include $3.7 million of gains, net of restructuring, as well as
intangibles amortization of $1.1 million.

OPTOELECTRONICS reported revenue of $83.3 million for the first quarter of 2003,
an increase of 20% from revenue of $69.3 million for the first quarter of 2002.
Strong double-digit growth in revenues of digital imaging and lighting products
drove the increase during the quarter. The segment's GAAP operating profit was
$8.7 million during the first quarter of 2003 versus an operating loss of $22.6
million for the comparable period of 2002. The operating profit for the first
quarter of 2003 included intangibles amortization of $.3 million. The operating
loss for the first quarter of 2002 included $21.0 million of aggregate charges
from restructuring and an inventory write-down, and intangibles amortization of
$.3 million.


                                            -more-

FLUID SCIENCES reported revenue of $42.9 million for the first quarter of 2003,
representing a decline of 4% compared to revenue of $44.6 million for the first
quarter in 2002. Both the aerospace and semiconductor end markets were depressed
during the quarter. The segment's GAAP operating profit for the first quarter of
2003 was $2.4 million versus $3.4 million in the first quarter of 2002. Included
in the results for the first quarter of 2003 was intangibles amortization of $.4
million. The first quarter of 2002 results included intangibles amortization of
$.2 million.

"We anticipate that global markets, particularly in capital spending, will
remain challenging throughout the year. Consequently, we are staying focused
on our strategy of reducing costs, accelerating new products, and driving cash
flow," added Summe.

The Company will discuss its first quarter results in a conference call on
Thursday, April 24, 2003 at 10:00 a.m. Eastern Time (ET). To listen to the call
live, please tune into the webcast at the Investor Relations section of our
website, www.perkinelmer.com. A playback of this conference call will be
available beginning at 1:00 p.m. ET, Thursday, April 24, 2003. The playback will
be available at the Investor Relations section of our website,
www.perkinelmer.com, or by telephone at (719) 457-0820, code number 442887.

FACTORS AFFECTING FUTURE PERFORMANCE

This press release contains "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Any statements contained
in this press release that relate to prospective events or developments are
deemed to be forward-looking statements. Words such as "believes,"
"anticipates," "plans," "expects," "projects," "forecasts," "will" and similar
expressions are intended to identify forward-looking statements. There are a
number of important factors that could cause actual results or events to differ
materially from those indicated by these forward-looking statements, including
risks related to our debt levels, our ability to comply with the financial
covenants contained in our credit agreements, a further downturn in our
customers' markets, our failure to introduce new products in a timely manner,
regulatory changes, risks related to our international operations, our inability
to integrate acquired businesses into our existing business and to successfully
combine our Life and Analytical Sciences businesses and competition, as well as
other factors which we describe under the caption "Forward-Looking Information
and Factors Affecting Future Performance" in our most recently filed annual
report on Form 10-K. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after the date
of this press release.


                                            -more-

PerkinElmer, Inc. is a global technology leader focused in the following
businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences.
Combining operational excellence and technology expertise with an intimate
understanding of our customers' needs, PerkinElmer provides products and
services in health sciences and other advanced technology markets that require
innovation, precision and reliability. The Company serves customers in more than
125 countries, and is a component of the S&P 500 Index. Additional information
is available through www.perkinelmer.com or 1-877-PKI-NYSE.

                                      # # #


For further information:

Investor Contact:                                    Media Contact:

Dan Sutherby                                         Jim Monahan
PerkinElmer, Inc.                                    PerkinElmer, Inc.
(781) 431-4306                                       (781) 431-4111